Nexplanon saw its best annual performance ever ... while biosimilars increased by 12% ex-FX for the year. Established brands ...

Wall Street analysts expect Organon (OGN) to post quarterly earnings of $0.92 per share in its upcoming report, which indicates a year-over-year decline of 24.6%. Revenues are expected to be $1.54 ...